Breakthrough Clinical Results
AL-S Pharma reported positive topline results from its Phase 2 clinical trial of AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1, for amyotrophic lateral sclerosis (ALS). The trial met its primary safety and tolerability endpoint. Clinically meaningful improvements in outcome measures related to survival and ventilation, along with biomarker stabilization, were observed after 12 months. The data will be presented at upcoming scientific conferences and submitted for publication. AL-S Pharma plans to engage with regulatory authorities.
Key Highlights
- Positive topline results from the Phase 2 clinical study of AP-101 for ALS.
- Met primary endpoint of safety and tolerability.
- Clinically meaningful changes observed in outcome measures and biomarker stabilization.
- Data to be presented at upcoming conferences and submitted for publication.
Study Design Parameters
Study Design Parameters and Endpoints in Key ALS Trials
Study Design Parameters
Double-blind randomized controlled trials (RCTs) or quasi-RCTs represent the standard design for ALS clinical trials. Participant selection typically includes adults with a diagnosis of probable or definite ALS according to criteria such as the revised El Escorial criteria. The Gold Coast consensus criteria have been proposed to simplify use and increase sensitivity for diagnosis, resulting in higher rates of clinical trial eligibility (95.2% vs 42.5% for riluzole trials, 100% vs 31.0% for edaravone trials).
Cohort enrichment strategies have been employed in trials like the edaravone development program (Studies 16 and 19) to elucidate treatment effects. Additionally, machine learning models are being utilized to create novel risk-based subgroup analysis tools to determine if results can be generalized to broader ALS populations.
Primary Endpoints
The primary efficacy endpoints in key ALS trials include: - Survival at one year from study enrollment - Change in the ALS Functional Rating Scale (ALSFRS-R) score from baseline (used in edaravone phase 3 studies) - For the ROCK-ALS phase 2 trial of fasudil, the co-primary endpoints were safety until day 180 and tolerability during the treatment period - The phase 2 trial of AMX0035 demonstrated statistically significant effects in slowing the rate of ALS progression
Secondary Endpoints
Secondary endpoints commonly assessed in ALS trials include: - Individual rate of decline of maximum voluntary isometric contraction (MVIC), expressed as arm megascore - Rate of decline of percent predicted forced vital capacity (FVC) - Rate of decline of ALS Functional Rating Scale (ALSFRS) - Health-related quality of life measurements - Survival evaluated by pooling hazards - Adverse events - Long-term patient survival (AMX0035 and Riluzole) - Serious adverse reactions and serious adverse events (edaravone)
Emerging Biomarkers and Assessment Tools
Several biomarkers and assessment tools are being developed for ALS trials: - Neuroimaging biomarkers including MRI and PET-derived metrics - Diffusion Tensor Imaging (DTI) parameters, particularly fractional anisotropy (FA) - The ALS Bulbar Dysfunction Index (ALS-BDI) - RNA sequencing (RNA-seq) of patient peripheral blood - MRI-derived biomarkers including MAP-derived indices - Multiple speech biomarkers - SNAP-25 CSF concentrations
Limitations in Current Trial Design
Current ALS trial designs have significant limitations: - Only 35% of trials assessed neuropsychiatric symptoms and only 22% assessed cognition - Only 3% of trials assessed neuropsychiatric symptoms as a Secondary Outcome Measure - Only 4% of trials assessed cognition as Outcome Measures - Only one trial included assessments for both cognition and neuropsychiatric symptoms as Outcome Measures
These limitations highlight the need for more comprehensive assessment approaches in future ALS clinical trials that address the full spectrum of disease manifestations.
Incidence and Prevalence
Global ALS Epidemiology Trends: Latest Estimates
Prevalence Estimates
-
In the United States, ALS prevalence has shown an increasing trend:
-
3.9 cases per 100,000 persons during 2010-2011
-
Updated to 4.3 per 100,000 with 13,282 total cases for October 19, 2010-December 31, 2011
-
4.7 cases per 100,000 for 2012
-
5.0 per 100,000 for 2013
-
In Norway, ALS prevalence remained stable at 7.6/100,000 (95% CI 6.9-8.4) as of December 31, 2015
-
In Japan, the annual crude prevalence rate was 9.9 (95% CI 9.7-10.1) per 100,000 people in 2009-2010
-
In the Faroe Islands, the 2020 crude prevalence was 9.5/100,000 (95% CI, 3.0-19.6) in a population of 52,912 inhabitants
-
According to a 2024 review, global ALS prevalence varies with incidence rates ranging from 1.5 to 3.8 per 100,000 individuals, significantly affecting populations aged 45-80
Incidence Estimates
-
In Japan, the annual crude incidence rate was 2.2 (95% CI 2.1-2.3) per 100,000 people in 2009-2010, with an age and sex-adjusted rate of 2.3 (95% CI 2.2-2.4)
-
In Cuba, the adjusted death rate from ALS for the population older than 15 years was 0.83 per 100,000
-
In the Faroe Islands, the 2010-2020 crude incidence was 4.9/100,000 person-years (95% CI, 3.3-7.0), with an age- and sex-standardized incidence of 4.1/100,000 person-years (95% CI, 2.7-6.0) - a 68% increase from the 1987-2009 estimate
Demographic and Regional Patterns
-
ALS is more common among whites, males, and persons aged 60-69 years
-
In the US, the lowest number of cases occur in persons aged 18-39 years and those ≥80 years
-
In Japan, the highest prevalence and incidence is in the 70-79 years age group, with a male-female ratio of approximately 1.5
-
In Norway, the male:female ratio was higher for prevalence (1.8; 95% CI 1.6-2.0) than for mortality (1.5; 95% CI 1.2-1.8)
-
Significant regional variations exist:
-
The incidence in Japanese populations is lower than in Caucasian populations of Europe and North America
-
In Cuba, rates are lower in mixed populations (0.55) compared to whites (0.93) and blacks (0.87)
-
Within Japan, some prefectures had significantly high standardized incidence ratios
-
Norway shows significant regional differences in prevalence but not in mortality
-
The worldwide distribution of ALS is far from uniform, with comprehensive epidemiological studies lacking in many parts of the world, especially in Africa
Drug used in other indications
AP-101 Clinical Trials Beyond ALS
Based on a thorough review of available information, there is no data on AP-101 being trialed for any indications, including Amyotrophic Lateral Sclerosis (ALS).
The experimental compound AP-101 does not appear in any clinical trial records in the available information. Without confirmed clinical trials, there are no documented intervention models, dosing regimens, or administration protocols to report.
For patients and researchers interested in novel therapeutics for ALS and other neurological conditions, it would be advisable to consult official clinical trial registries such as ClinicalTrials.gov or contact pharmaceutical companies directly for the most current information on emerging treatments.
The development of new therapeutic agents for neurological disorders remains an active area of research, with numerous compounds in various stages of the clinical trial pipeline. However, specific information regarding AP-101's development status, target indications beyond ALS, or intervention methodologies cannot be determined from the available data.